Agreement Leverages Vifor Pharma's Exclusive Distribution Arrangement with Certain Dialysis Organizations
Agreement Defines Profit Share Economics of Potential Vadadustat Revenue if Approved
- Vifor Pharma to make equity purchase of $20 million
- $40 million refundable working capital investment to partially fund launch supply
- $25 million upfront payment
https://finance.yahoo.com/news/akebia-therapeutics-announces-amendment-license-133000797.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.